Emmanuelle Marie Butty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Emmanuelle Marie Butty has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Mary Anna Labato
Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA
5 shared publications Alessio Vigani
Clinic for Small Animal Medicine, Vetsuisse Faculty, University of Zurich , Zurich
2 shared publications- Alex Michael Lynch
Department of Clinical Sciences, College of Veterinary Medicine North Carolina State University Raleigh North Carolina USA
2 shared publications Caryn M. Ehrhardt
University of Florida, College of Veterinary Medicine Department of Small Animal Clinical Sciences Gainesville, Florida
2 shared publicationsChristine A. Culler
BluePearl Pet Hospital , Cary, North Carolina
2 shared publicationsJames B. Robertson
North Carolina State University, College of Veterinary Medicine Department of Clinical Sciences Raleigh, North Carolina
2 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- p. 1-8
Elimination kinetics of nonsteroidal anti-inflammatory drugs during carbon hemoperfusion in 19 dogs with toxicosis
Objective: To describe the elimination kinetics of NSAIDs during carbon hemoperfusion (cHP) in dogs with toxicosis, specifically the apparent elimination rate constant, half-life, and plasma reduction. Methods: 19 client-owned dogs (median age, 2.5 years; median body weight, 22 kg) with ibuprofen (n = 10), carprofen (5), or naproxen (4) toxicosis treated with cHP at 2 academic veterinary teaching hospitals from November 30, 2022, through July 7, 2024. Dogs were presented after known or suspected ingestion at median estimated maximum doses of 720, 200, and 325 mg/kg for ibuprofen, carprofen, and naproxen, respectively. The median interval from ingestion to cHP was 6.8 hours. Plasma concentrations were measured by LC-MS-MS in-serial samples collected during and, when available, after cHP. Results: The median total plasma reduction was 58% (IQR, 51 to 80). The overall half-life during cHP was 1.3 hours (IQR, 1.1 to 1.8) by the 2-point method, concordant by regression (1.4 hours), and approximately 3.7-, 5.4-, and 52.0-fold shorter than respective therapeutic-dose half-lives. Among 5 dogs with posttreatment samples, plasma concentration rebounded after cHP in 1 naproxen-treated dog. The cHP-associated rate constant exceeded the intrinsic rate constant 11- to 40-fold in 4 of 5 dogs. Conclusions: Carbon hemoperfusion was associated with substantial reductions in plasma NSAID concentrations during treatment in dogs with severe ibuprofen, carprofen, or naproxen toxicosis. Most of the decline occurred early in the session. Further studies are warranted to optimize treatment protocols. Clinical Relevance: Carbon hemoperfusion markedly shortened NSAID elimination half-lives in dogs with severe toxicosis, accelerating removal well beyond endogenous elimination.
- 4 November 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- p. 1-8
Open AccessElimination kinetics of nonsteroidal anti-inflammatory drugs during carbon hemoperfusion in 19 dogs with toxicosis
Objective: To describe the elimination kinetics of NSAIDs during carbon hemoperfusion (cHP) in dogs with toxicosis, specifically the apparent elimination rate constant, half-life, and plasma reduction. Methods: 19 client-owned dogs (median age, 2.5 years; median body weight, 22 kg) with ibuprofen (n = 10), carprofen (5), or naproxen (4) toxicosis treated with cHP at 2 academic veterinary teaching hospitals from November 30, 2022, through July 7, 2024. Dogs were presented after known or suspected ingestion at median estimated maximum doses of 720, 200, and 325 mg/kg for ibuprofen, carprofen, and naproxen, respectively. The median interval from ingestion to cHP was 6.8 hours. Plasma concentrations were measured by LC-MS-MS in-serial samples collected during and, when available, after cHP. Results: The median total plasma reduction was 58% (IQR, 51 to 80). The overall half-life during cHP was 1.3 hours (IQR, 1.1 to 1.8) by the 2-point method, concordant by regression (1.4 hours), and approximately 3.7-, 5.4-, and 52.0-fold shorter than respective therapeutic-dose half-lives. Among 5 dogs with posttreatment samples, plasma concentration rebounded after cHP in 1 naproxen-treated dog. The cHP-associated rate constant exceeded the intrinsic rate constant 11- to 40-fold in 4 of 5 dogs. Conclusions: Carbon hemoperfusion was associated with substantial reductions in plasma NSAID concentrations during treatment in dogs with severe ibuprofen, carprofen, or naproxen toxicosis. Most of the decline occurred early in the session. Further studies are warranted to optimize treatment protocols. Clinical Relevance: Carbon hemoperfusion markedly shortened NSAID elimination half-lives in dogs with severe toxicosis, accelerating removal well beyond endogenous elimination.
- Open Access
- 28 November 2025
- Published by Elsevier in The Veterinary Journal
- Vol. 315, 106519
Hemoperfusion for veterinary toxicities: International renal interest society best practices consensus guidelines
- 28 November 2025
- Published by Elsevier in The Veterinary Journal
- Vol. 315, 106519
Open AccessHemoperfusion for veterinary toxicities: International renal interest society best practices consensus guidelines
- Open Access
- 1 July 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (4)
Retrospective Evaluation of Risk Factors and Outcome in Dogs With and Without Fluid Overload During Hospitalization
Background: Risk factors for the development of fluid overload (FO) and its potential negative effects have not been investigated in dogs. Hypothesis/Objectives: Evaluate risk factors and outcomes in hospitalized dogs that received fluids IV and developed clinical signs of FO compared to those that did not. Animals: One hundred thirty-six dogs that developed FO and 109 dogs without FO. Methods: Retrospective observational study of hospitalized dogs. Variables were compared between dogs that developed clinical signs of FO (FO group) and dogs without FO (control group). Results: Compared to the control group, dogs in the FO group were significantly more likely to have cardiovascular disease (odds ratio [OR], 18.1; 95% confidence interval [CI], 5.4–60), protein-losing nephropathy (OR, 15.3; 95% CI, 2.0–116.8), chronic kidney disease (OR, 10; 95% CI, 3.0–33.8), and acute kidney injury (OR, 5.2; 95% CI, 2.5–10.6). The total fluid volume administered IV was not significantly different between the groups (p = 0.16). Only 6.0% of dogs with clinical signs of FO gained > 10% weight from non-dehydrated baseline and thus met the FO definition used in human medicine. Compared with the control group, dogs with FO had a significantly longer median duration of hospitalization (p < 0.001) and were less likely to survive to discharge (p < 0.001). Conclusions and Clinical Importance: FO was more common with certain underlying diseases but not associated with total fluid volume administered IV. The definition for FO in human medicine using weight gain requires further evaluation in dogs. FO was associated with worse outcomes and longer hospitalization time.
- 1 July 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (4)
Open AccessRetrospective Evaluation of Risk Factors and Outcome in Dogs With and Without Fluid Overload During Hospitalization
Background: Risk factors for the development of fluid overload (FO) and its potential negative effects have not been investigated in dogs. Hypothesis/Objectives: Evaluate risk factors and outcomes in hospitalized dogs that received fluids IV and developed clinical signs of FO compared to those that did not. Animals: One hundred thirty-six dogs that developed FO and 109 dogs without FO. Methods: Retrospective observational study of hospitalized dogs. Variables were compared between dogs that developed clinical signs of FO (FO group) and dogs without FO (control group). Results: Compared to the control group, dogs in the FO group were significantly more likely to have cardiovascular disease (odds ratio [OR], 18.1; 95% confidence interval [CI], 5.4–60), protein-losing nephropathy (OR, 15.3; 95% CI, 2.0–116.8), chronic kidney disease (OR, 10; 95% CI, 3.0–33.8), and acute kidney injury (OR, 5.2; 95% CI, 2.5–10.6). The total fluid volume administered IV was not significantly different between the groups (p = 0.16). Only 6.0% of dogs with clinical signs of FO gained > 10% weight from non-dehydrated baseline and thus met the FO definition used in human medicine. Compared with the control group, dogs with FO had a significantly longer median duration of hospitalization (p < 0.001) and were less likely to survive to discharge (p < 0.001). Conclusions and Clinical Importance: FO was more common with certain underlying diseases but not associated with total fluid volume administered IV. The definition for FO in human medicine using weight gain requires further evaluation in dogs. FO was associated with worse outcomes and longer hospitalization time.
- Open Access
- 1 March 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (2) , 1051-1059
Retrospective evaluation of 22 dogs with leptospirosis treated with extracorporeal renal replacement therapies (2018-2021)
Background: Outcomes of dogs with acute kidney injury secondary to leptospirosis (AKI-L) treated using renal replacement therapies (RRT) are poorly characterized. Hypothesis/Objectives: Describe survival to discharge, short (≤30 days) and long-term (≥6 months) outcomes of AKI-L dogs receiving RRT and determine if there is a significant difference in maximum blood urea nitrogen (maxBUN), maximum creatinine (maxCr), maximum bilirubin (maxBili) and the number of body systems affected between survivors and non-survivors. Animals: Twenty-two client-owned dogs with AKI-L receiving RRT. Methods: Retrospective medical record review of dogs with AKI-L that received RRT between 2018 and 2021. Results: Sixteen of 22 (73%) dogs survived to discharge. Of the survivors, 13 (81%) were alive >30 days from discharge and 12 (75%) were alive at 6 months from discharge. Factors significantly higher in non-survivors included number of body systems affected (survivors: 1 (19%), 2 (50%), 3 (25%) and 4 (6%) vs non-survivors: 3 (33.3%), and 4 (66.7%); P = .01) and median maxBili (survivors: 1.9 mg/dL; range, 0.1-41.6 vs non-survivors: 21.0 mg/dL; range, 12.3-38.9; P = .02). There was no significant difference in median maxBUN (survivors: 153.0 mg/dL; range, 67-257 vs non-survivors: 185.5 mg/dL; range, 102-218; P = .44) and median maxCr (survivors: 9.8 mg/dL; range, 6.2-15.9 vs non-survivors: 9.8 mg/dL; range, 8.4-13.5; P = .69) between survivors and non-survivors. Conclusions and Clinical Importance: Regardless of azotemia severity, dogs with AKI-L receiving RRT have a good survival rate to discharge. The number of body systems affected and hyperbilirubinemia might be associated with worse outcomes.
- 1 March 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (2) , 1051-1059
Open AccessRetrospective evaluation of 22 dogs with leptospirosis treated with extracorporeal renal replacement therapies (2018-2021)
Background: Outcomes of dogs with acute kidney injury secondary to leptospirosis (AKI-L) treated using renal replacement therapies (RRT) are poorly characterized. Hypothesis/Objectives: Describe survival to discharge, short (≤30 days) and long-term (≥6 months) outcomes of AKI-L dogs receiving RRT and determine if there is a significant difference in maximum blood urea nitrogen (maxBUN), maximum creatinine (maxCr), maximum bilirubin (maxBili) and the number of body systems affected between survivors and non-survivors. Animals: Twenty-two client-owned dogs with AKI-L receiving RRT. Methods: Retrospective medical record review of dogs with AKI-L that received RRT between 2018 and 2021. Results: Sixteen of 22 (73%) dogs survived to discharge. Of the survivors, 13 (81%) were alive >30 days from discharge and 12 (75%) were alive at 6 months from discharge. Factors significantly higher in non-survivors included number of body systems affected (survivors: 1 (19%), 2 (50%), 3 (25%) and 4 (6%) vs non-survivors: 3 (33.3%), and 4 (66.7%); P = .01) and median maxBili (survivors: 1.9 mg/dL; range, 0.1-41.6 vs non-survivors: 21.0 mg/dL; range, 12.3-38.9; P = .02). There was no significant difference in median maxBUN (survivors: 153.0 mg/dL; range, 67-257 vs non-survivors: 185.5 mg/dL; range, 102-218; P = .44) and median maxCr (survivors: 9.8 mg/dL; range, 6.2-15.9 vs non-survivors: 9.8 mg/dL; range, 8.4-13.5; P = .69) between survivors and non-survivors. Conclusions and Clinical Importance: Regardless of azotemia severity, dogs with AKI-L receiving RRT have a good survival rate to discharge. The number of body systems affected and hyperbilirubinemia might be associated with worse outcomes.
- Open Access
- 1 September 2023
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 37 (5) , 1806-1814
Pseudomembranous cystitis in cats with presumed or confirmed mineralization: A retrospective study of 26 cases (2016-2021)
Background: Pseudomembranous cystitis (PMC) in cats is a recognized disease, but concurrent mineralization is reported rarely and its outcome is poorly described. Hypothesis and Objectives: Describe a population of cats with PMC and the prevalence of concurrent mineralization. Animals: Twenty-six cats with PMC. Methods: Medical records were retrospectively reviewed (January 2016 to December 2021). Cats with an ultrasound diagnosis of PMC were included. Clinicopathologic results, imaging, treatment, and outcome were reviewed. Results: All cats were male and 21 (80%) were diagnosed with urethral obstruction (UO). Five cats (23.8%) had positive urine culture (Staphylococcus felis, 3/5; Proteus mirabilis, 2/5) with a median urine pH of 8 (range, 6-9). All cats had ultrasonographic changes suggestive of mineralization. On ultrasound examination, 10 cats (38.5%) had pseudomembranes with acoustic shadowing suggestive of mineralization, 15 (57.7%) had changes indicative of ulceration, and 8 (31%) had changes compatible with of a urachal anomaly. Twenty-two cats received medical treatment, 4 underwent surgery (3 percutaneous cystolithotomy, 1 cystotomy). Twenty cats (77%) survived to discharge. Follow-up ultrasound examination indicated resolution of PMC in 6/7 cats, 4 had persistent hyperechoic bladder lining. Five of 12 cats with follow-up had a relapse of lower urinary tract signs. Conclusions and Clinical Importance: Pseudomembranous cystitis was diagnosed mainly in male cats with UO and imaging findings suggestive of mineralization were present in all cases. Frequent negative urine culture suggests a different etiology than encrusting cystitis related to urease-positive bacteria. Good outcomes can be achieved with medical management.
- 1 September 2023
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 37 (5) , 1806-1814
Open AccessPseudomembranous cystitis in cats with presumed or confirmed mineralization: A retrospective study of 26 cases (2016-2021)
Background: Pseudomembranous cystitis (PMC) in cats is a recognized disease, but concurrent mineralization is reported rarely and its outcome is poorly described. Hypothesis and Objectives: Describe a population of cats with PMC and the prevalence of concurrent mineralization. Animals: Twenty-six cats with PMC. Methods: Medical records were retrospectively reviewed (January 2016 to December 2021). Cats with an ultrasound diagnosis of PMC were included. Clinicopathologic results, imaging, treatment, and outcome were reviewed. Results: All cats were male and 21 (80%) were diagnosed with urethral obstruction (UO). Five cats (23.8%) had positive urine culture (Staphylococcus felis, 3/5; Proteus mirabilis, 2/5) with a median urine pH of 8 (range, 6-9). All cats had ultrasonographic changes suggestive of mineralization. On ultrasound examination, 10 cats (38.5%) had pseudomembranes with acoustic shadowing suggestive of mineralization, 15 (57.7%) had changes indicative of ulceration, and 8 (31%) had changes compatible with of a urachal anomaly. Twenty-two cats received medical treatment, 4 underwent surgery (3 percutaneous cystolithotomy, 1 cystotomy). Twenty cats (77%) survived to discharge. Follow-up ultrasound examination indicated resolution of PMC in 6/7 cats, 4 had persistent hyperechoic bladder lining. Five of 12 cats with follow-up had a relapse of lower urinary tract signs. Conclusions and Clinical Importance: Pseudomembranous cystitis was diagnosed mainly in male cats with UO and imaging findings suggestive of mineralization were present in all cases. Frequent negative urine culture suggests a different etiology than encrusting cystitis related to urease-positive bacteria. Good outcomes can be achieved with medical management.
- Open Access
- 1 January 2023
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 37 (1) , 161-172
Outcomes of 434 dogs with non-steroidal anti-inflammatory drug toxicosis treated with fluid therapy, lipid emulsion, or therapeutic plasma exchange
Background: Traditional management of non-steroidal anti-inflammatory drug (NSAID) intoxication includes gastrointestinal decontamination, intravenous administration of fluids (IVF), and gastroprotection. Intravenous administration of lipid emulsion (ILE) and therapeutic plasma exchange (TPE) are popular novel therapeutic strategies. Hypothesis: Compare outcomes of dogs treated with IVF, ILE, and TPE for NSAID intoxications and evaluate outcome predictors for drug subgroups. Animals: Four hundred thirty-four dogs with NSAID intoxications (2015-2020). Methods: Multicenter retrospective study of ibuprofen, carprofen, and naproxen intoxication. An ordinal outcome was defined as mild gastrointestinal, moderate kidney, or signs of severe central nervous system disease. Results: Signs of neurological disease were overrepresented and acute kidney injury underrepresented in the TPE group among dogs exposed to kidney- or CNS-toxic doses (P = .05), though all TPE dogs with signs of neurological disease had evidence of neurotoxicity at presentation. Dogs treated with IVF had a higher maximal creatinine concentration (median, 1.1 mg/dL; range, 0.4-8.44 mg/dL) compared with IVF + ILE (median, 0.9 mg/dL; range, 0.4-6.2 mg/dL; P = .01). Increased maximum time to presentation (P < .001), higher baseline creatinine (P < .001) and PCV (P = .007), and absence of induced emesis (P < .001) were associated with greater clinical severity. Ibuprofen toxicosis was associated with more severe clinical signs compared with carprofen (P = .03). Overall survival rate was 99%. Conclusions and Clinical Importance: NSAID toxicosis generally carries an excellent prognosis in dogs. Despite similar outcomes of lower incidence of AKI in the TPE group, and slightly lower maximal creatinine concentration in dogs treated with ILE vs IVF alone, ILE and TPE should be considered in the management of severe NSAID toxicosis.
- 1 January 2023
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 37 (1) , 161-172
Open AccessOutcomes of 434 dogs with non-steroidal anti-inflammatory drug toxicosis treated with fluid therapy, lipid emulsion, or therapeutic plasma exchange
Background: Traditional management of non-steroidal anti-inflammatory drug (NSAID) intoxication includes gastrointestinal decontamination, intravenous administration of fluids (IVF), and gastroprotection. Intravenous administration of lipid emulsion (ILE) and therapeutic plasma exchange (TPE) are popular novel therapeutic strategies. Hypothesis: Compare outcomes of dogs treated with IVF, ILE, and TPE for NSAID intoxications and evaluate outcome predictors for drug subgroups. Animals: Four hundred thirty-four dogs with NSAID intoxications (2015-2020). Methods: Multicenter retrospective study of ibuprofen, carprofen, and naproxen intoxication. An ordinal outcome was defined as mild gastrointestinal, moderate kidney, or signs of severe central nervous system disease. Results: Signs of neurological disease were overrepresented and acute kidney injury underrepresented in the TPE group among dogs exposed to kidney- or CNS-toxic doses (P = .05), though all TPE dogs with signs of neurological disease had evidence of neurotoxicity at presentation. Dogs treated with IVF had a higher maximal creatinine concentration (median, 1.1 mg/dL; range, 0.4-8.44 mg/dL) compared with IVF + ILE (median, 0.9 mg/dL; range, 0.4-6.2 mg/dL; P = .01). Increased maximum time to presentation (P < .001), higher baseline creatinine (P < .001) and PCV (P = .007), and absence of induced emesis (P < .001) were associated with greater clinical severity. Ibuprofen toxicosis was associated with more severe clinical signs compared with carprofen (P = .03). Overall survival rate was 99%. Conclusions and Clinical Importance: NSAID toxicosis generally carries an excellent prognosis in dogs. Despite similar outcomes of lower incidence of AKI in the TPE group, and slightly lower maximal creatinine concentration in dogs treated with ILE vs IVF alone, ILE and TPE should be considered in the management of severe NSAID toxicosis.
- 1 September 2022
- Published by American Animal Hospital Association in Journal of the American Animal Hospital Association
- Vol. 58 (5) , 231-239
Irreversible Electroporation Balloon Therapy for Palliative Treatment of Obstructive Urethral Transitional Cell Carcinoma in Dogs
Progression of transitional cell carcinoma (TCC) in dogs often leads to urinary obstruction. This observational pilot study aimed to evaluate the safety and efficacy of irreversible electroporation (IRE) balloon therapy for the palliative treatment of TCC with partial urethral obstruction. Three client-owned dogs diagnosed with TCC causing partial urethral obstruction were enrolled. After ultrasonographic and cystoscopic examination, IRE pulse protocols were delivered through a balloon catheter device inflated within the urethral lumen. After the procedure, the patients were kept overnight for monitoring and a recheck was planned 28 days later. No complication was observed during the procedure and postprocedural monitoring. After 28 days, one dog had a complete normalization of the urine stream, one dog had stable stranguria, and one dog was presented with a urethral obstruction secondary to progression of the TCC. On recheck ultrasound, one dog had a 38% diminution of the urethral mass diameter whereas the other two dogs had a mass stable in size. IRE balloon therapy seems to be a feasible and apparently safe minimally invasive novel therapy for the palliative treatment of TCC causing urethral obstruction. Further studies are needed to better characterize the safety, efficacy, and outcome of this therapy.
- 1 September 2022
- Published by American Animal Hospital Association in Journal of the American Animal Hospital Association
- Vol. 58 (5) , 231-239
Irreversible Electroporation Balloon Therapy for Palliative Treatment of Obstructive Urethral Transitional Cell Carcinoma in Dogs
Progression of transitional cell carcinoma (TCC) in dogs often leads to urinary obstruction. This observational pilot study aimed to evaluate the safety and efficacy of irreversible electroporation (IRE) balloon therapy for the palliative treatment of TCC with partial urethral obstruction. Three client-owned dogs diagnosed with TCC causing partial urethral obstruction were enrolled. After ultrasonographic and cystoscopic examination, IRE pulse protocols were delivered through a balloon catheter device inflated within the urethral lumen. After the procedure, the patients were kept overnight for monitoring and a recheck was planned 28 days later. No complication was observed during the procedure and postprocedural monitoring. After 28 days, one dog had a complete normalization of the urine stream, one dog had stable stranguria, and one dog was presented with a urethral obstruction secondary to progression of the TCC. On recheck ultrasound, one dog had a 38% diminution of the urethral mass diameter whereas the other two dogs had a mass stable in size. IRE balloon therapy seems to be a feasible and apparently safe minimally invasive novel therapy for the palliative treatment of TCC causing urethral obstruction. Further studies are needed to better characterize the safety, efficacy, and outcome of this therapy.
- Open Access
- 5 August 2022
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 36 (5) , 1641-1647
Outcomes of nonsteroidal anti-inflammatory drug toxicosis treated with therapeutic plasma exchange in 62 dogs
Background: Therapeutic plasma exchange (TPE) is gaining popularity for the management of nonsteroidal anti-inflammatory drug (NSAID) overdose in dogs. Hypothesis/Objectives: Describe a population of dogs treated with TPE for NSAID overdose. Animals: Sixty-two dogs with NSAID overdose treated with TPE. Methods: Multicenter retrospective study of dogs treated with TPE for ibuprofen, carprofen, or naproxen overdose. Results: The median dose of ibuprofen, carprofen or naproxen ingested was 533 mg/kg (range, 36-4857 mg/kg), 217 mg/kg (range, 88-625 mg/kg) and 138 mg/kg (range, 26-3000 mg/kg), respectively. Based on previously established toxic ranges for each NSAID, 2 (3.2%), 14 (22.6%), and 46 (74.2%) dogs ingested a gastrointestinal, renal, and neurological toxic dose, respectively. The median time between ingestion and presentation was 4 hours (range, 1-20 hours). The median number of plasma volumes processed was 1.6 (range, 0.4-2.2). The median TPE session duration was 2 hours (range, 1-4.5 hours). Circuit clotting developed during 8 (12.9%) sessions. Patient adverse events reported during 21 (33.8%) sessions consisted of urticaria (12.9%), asymptomatic hypocalcemia (9.6%), and hypotension (9.6%). The median duration of hospitalization was 2.25 days (range, 1-11 days). Sixty-one (98.4%) dogs survived to discharge, and none were rehospitalized. Thirty-one (91.1%) of the 34 dogs with at least 1 follow-up visit were not azotemic at the time of reevaluation. Conclusions and Clinical Importance: This population of dogs managed with TPE had excellent outcomes, even in cases of high NSAID dose ingestion. When TPE is available and the time frame is appropriate, this extracorporeal modality should be considered for the management of NSAID overdose.
- 5 August 2022
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 36 (5) , 1641-1647
Open AccessOutcomes of nonsteroidal anti-inflammatory drug toxicosis treated with therapeutic plasma exchange in 62 dogs
Background: Therapeutic plasma exchange (TPE) is gaining popularity for the management of nonsteroidal anti-inflammatory drug (NSAID) overdose in dogs. Hypothesis/Objectives: Describe a population of dogs treated with TPE for NSAID overdose. Animals: Sixty-two dogs with NSAID overdose treated with TPE. Methods: Multicenter retrospective study of dogs treated with TPE for ibuprofen, carprofen, or naproxen overdose. Results: The median dose of ibuprofen, carprofen or naproxen ingested was 533 mg/kg (range, 36-4857 mg/kg), 217 mg/kg (range, 88-625 mg/kg) and 138 mg/kg (range, 26-3000 mg/kg), respectively. Based on previously established toxic ranges for each NSAID, 2 (3.2%), 14 (22.6%), and 46 (74.2%) dogs ingested a gastrointestinal, renal, and neurological toxic dose, respectively. The median time between ingestion and presentation was 4 hours (range, 1-20 hours). The median number of plasma volumes processed was 1.6 (range, 0.4-2.2). The median TPE session duration was 2 hours (range, 1-4.5 hours). Circuit clotting developed during 8 (12.9%) sessions. Patient adverse events reported during 21 (33.8%) sessions consisted of urticaria (12.9%), asymptomatic hypocalcemia (9.6%), and hypotension (9.6%). The median duration of hospitalization was 2.25 days (range, 1-11 days). Sixty-one (98.4%) dogs survived to discharge, and none were rehospitalized. Thirty-one (91.1%) of the 34 dogs with at least 1 follow-up visit were not azotemic at the time of reevaluation. Conclusions and Clinical Importance: This population of dogs managed with TPE had excellent outcomes, even in cases of high NSAID dose ingestion. When TPE is available and the time frame is appropriate, this extracorporeal modality should be considered for the management of NSAID overdose.
- Open Access
- 1 May 2021
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 35 (3) , 1626-1630
Treatment of a flunixin meglumine overdose with intravenous administration of lipid emulsion and therapeutic plasma exchange in a Nigerian dwarf buck kid ( Capra aegagrus hircus )
A 12 week‐old Nigerian dwarf (Capra aegagrus hircus) buck kid was hospitalized for management of obstructive urolithiasis. Postoperatively, he was inadvertently administered 16‐times greater than his calculated dose of a nonsteroidal anti‐inflammatory drug (NSAID; 17.5 mg/kg flunixin meglumine, IV). The goat was treated with intravenous administration of lipid emulsion (ILE) prior to membrane‐based therapeutic plasma exchange (mTPE) under general anesthesia. The increased coagulability inherent to small ruminants in comparison with dogs and cats warranted specific adjustments in the prescription of anticoagulation, blood flow, and filtration fraction to avoid circuit clotting during mTPE. Serum flunixin meglumine concentration measured before, during, and after mTPE revealed marked reduction in drug concentration. After the combined treatments, no clinical evidence of NSAID gastrointestinal or renal toxicosis was detected. This case report describes successful management of flunixin meglumine overdose in a small ruminant using combined ILE and mTPE.
- 1 May 2021
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 35 (3) , 1626-1630
Open AccessTreatment of a flunixin meglumine overdose with intravenous administration of lipid emulsion and therapeutic plasma exchange in a Nigerian dwarf buck kid ( Capra aegagrus hircus )
A 12 week‐old Nigerian dwarf (Capra aegagrus hircus) buck kid was hospitalized for management of obstructive urolithiasis. Postoperatively, he was inadvertently administered 16‐times greater than his calculated dose of a nonsteroidal anti‐inflammatory drug (NSAID; 17.5 mg/kg flunixin meglumine, IV). The goat was treated with intravenous administration of lipid emulsion (ILE) prior to membrane‐based therapeutic plasma exchange (mTPE) under general anesthesia. The increased coagulability inherent to small ruminants in comparison with dogs and cats warranted specific adjustments in the prescription of anticoagulation, blood flow, and filtration fraction to avoid circuit clotting during mTPE. Serum flunixin meglumine concentration measured before, during, and after mTPE revealed marked reduction in drug concentration. After the combined treatments, no clinical evidence of NSAID gastrointestinal or renal toxicosis was detected. This case report describes successful management of flunixin meglumine overdose in a small ruminant using combined ILE and mTPE.
- 23 March 2021
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 23 (12) , 1183-1191
Subcutaneous ureteral bypass device placement with intraoperative ultrasound guidance, with or without microsurgical ureterotomy, in 24 cats
The aim of this study was to describe a method of subcutaneous ureteral bypass (SUB) device placement with intraoperative ultrasound guidance, with or without microsurgical ureterotomy, for the treatment of benign ureteral obstruction(s) in cats. A secondary aim was to describe the complications and outcomes in our population, and compare the two groups with and without ureterotomy. The medical records of cats with benign ureteral obstruction(s) treated with SUB device placement with intraoperative ultrasound guidance between April 2013 and June 2018 were reviewed. Twenty-four cats with 30 obstructed ureters had a SUB device placement with intraoperative ultrasound guidance in 26 surgeries. A microsurgical ureterotomy was performed in 14/26 surgeries. Median age was 10.07 years (range 4–16.6). Eleven of 24 cats (46%) had a previous history of chronic kidney disease (CKD). All cats, including two patients with minimal pelvic dilation (⩽4 mm), had a successful intrapelvic placement of the SUB device. Median survival time was 1555 days (4.25 years); this was not significantly different between the two groups (P = 0.4494). Stone analysis and bacterial culture, where available for review, revealed calcium oxalate in 12/12 and a negative culture in 6/7. The ureterotomy significantly prolonged the procedure duration (180 vs 125 mins) without significantly decreasing the short- and long-term complications (P = 0.1588 and P = 0.2921, respectively), or the survival time (P = 0.8437). SUB device placement with intraoperative ultrasound guidance is an effective alternative for the treatment of ureteral obstruction. Ultrasound guidance may be a more accessible option when a trained veterinarian does not have access to fluoroscopy. Microsurgical ureterotomy did not show any advantage and prolonged the anesthesia. Our median survival time emphasizes a good outcome of SUB device placement, even in cats with a previous history of CKD.
- 23 March 2021
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 23 (12) , 1183-1191
Subcutaneous ureteral bypass device placement with intraoperative ultrasound guidance, with or without microsurgical ureterotomy, in 24 cats
The aim of this study was to describe a method of subcutaneous ureteral bypass (SUB) device placement with intraoperative ultrasound guidance, with or without microsurgical ureterotomy, for the treatment of benign ureteral obstruction(s) in cats. A secondary aim was to describe the complications and outcomes in our population, and compare the two groups with and without ureterotomy. The medical records of cats with benign ureteral obstruction(s) treated with SUB device placement with intraoperative ultrasound guidance between April 2013 and June 2018 were reviewed. Twenty-four cats with 30 obstructed ureters had a SUB device placement with intraoperative ultrasound guidance in 26 surgeries. A microsurgical ureterotomy was performed in 14/26 surgeries. Median age was 10.07 years (range 4–16.6). Eleven of 24 cats (46%) had a previous history of chronic kidney disease (CKD). All cats, including two patients with minimal pelvic dilation (⩽4 mm), had a successful intrapelvic placement of the SUB device. Median survival time was 1555 days (4.25 years); this was not significantly different between the two groups (P = 0.4494). Stone analysis and bacterial culture, where available for review, revealed calcium oxalate in 12/12 and a negative culture in 6/7. The ureterotomy significantly prolonged the procedure duration (180 vs 125 mins) without significantly decreasing the short- and long-term complications (P = 0.1588 and P = 0.2921, respectively), or the survival time (P = 0.8437). SUB device placement with intraoperative ultrasound guidance is an effective alternative for the treatment of ureteral obstruction. Ultrasound guidance may be a more accessible option when a trained veterinarian does not have access to fluoroscopy. Microsurgical ureterotomy did not show any advantage and prolonged the anesthesia. Our median survival time emphasizes a good outcome of SUB device placement, even in cats with a previous history of CKD.